View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
March 3, 2021

WuXi AppTec strengthens gene therapy offerings with OXGENE acquisition

WuXi AppTec has concluded the acquisition of UK-based contract research and development organisation OXGENE to further advance its cell and gene therapy service offerings for customers across the globe.

WuXi AppTec has concluded the acquisition of UK-based contract research and development organisation OXGENE to boost its cell and gene therapy services for customers worldwide.

Free Report
img

What’s missing from your IPO industry assessment?

IPO activity all but stopped in 2020, as the investment community grew wary of the effects of COVID-19 on economies. No matter how deserving a business was of flotation, momentum was halted by concerns of when a ‘new normal’ of working patterns and trade would set in. Recently, sentiment has changed. Flotations picked up again during the second half of 2021, and now in 2022 the mood is decidedly optimistic. Business leaders have their eyes on fast rebounding economies, buoyant market indices and the opportunity once again to take their businesses public. As a result, global IPOs are expected to hit back this year. With GlobalData’s new whitepaper, ‘IPOs in Consumer and Retail: 5 must-include elements for your prospectus industry report’, you can explore exactly what is needed in the essential literature. GlobalData’s focus lies in the critical areas to get right:
  • Macroeconomic and demographic environment
  • Consumer context
  • Industry environment
  • Competitive environment
  • Route to market
Interested to learn more about what to include in your IPO Industry Assessment report? Download our free whitepaper.
by GlobalData
Enter your details here to receive your free Report.

OXGENE will now be a fully owned subsidiary of WuXi Advanced Therapies (WuXi ATU), the cell and gene therapy Contract Testing, Development and Manufacturing Organisation (CTDMO) business unit of WuXi AppTec.

Transforming the development, testing, production and sale of cell and gene therapy products, the integrated platforms of the company expedite their time to market.

ROXGENE will retain its name and feature as WuXi ATU’s first facility in Europe, which will boost its capabilities.

OXGENE founder and CEO Dr Ryan Cawood said: “OXGENE is proud to have invented a range of next-generation platforms that address the complexities of viral vector manufacturing for gene and cell therapies.

“We are excited to join the team at WuXi ATU and to work together to scale up our technologies as a combined business, which will strengthen and broaden our service offerings for customers, improved by orders of the scale and cost of bringing cell and gene therapies to market.”

Founded in 2011, the company has provided discovery and biomanufacturing solutions to cell and gene therapy industries by using new technologies and contract research solutions.

Furthermore, it offers manufacturing systems that provide exceptional scalability.

Through its new TESSA technology for adeno-associated viral (AAV) manufacturing, as well as the XLenti stable solutions for lentiviral manufacturing, the company can streamline cell and gene therapy production and cut down costs.

WuXi ATU CEO Dr David Chang said: “By combining WuXi ATU’s world-class cell and gene therapy CTDMO platform with OXGENE’s innovative capabilities, we will be able to provide transformative solutions for our customers.

“This business combination represents a significant step in our ongoing effort to enable our customers and partners worldwide to deliver more effective and accessible advanced therapies to patients globally.”

Related Companies

Free Report
img

What’s missing from your IPO industry assessment?

IPO activity all but stopped in 2020, as the investment community grew wary of the effects of COVID-19 on economies. No matter how deserving a business was of flotation, momentum was halted by concerns of when a ‘new normal’ of working patterns and trade would set in. Recently, sentiment has changed. Flotations picked up again during the second half of 2021, and now in 2022 the mood is decidedly optimistic. Business leaders have their eyes on fast rebounding economies, buoyant market indices and the opportunity once again to take their businesses public. As a result, global IPOs are expected to hit back this year. With GlobalData’s new whitepaper, ‘IPOs in Consumer and Retail: 5 must-include elements for your prospectus industry report’, you can explore exactly what is needed in the essential literature. GlobalData’s focus lies in the critical areas to get right:
  • Macroeconomic and demographic environment
  • Consumer context
  • Industry environment
  • Competitive environment
  • Route to market
Interested to learn more about what to include in your IPO Industry Assessment report? Download our free whitepaper.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology